Business Context and Reporting Period
uniQure N.V. (QURE) is a gene therapy company focused on developing single treatments for rare and devastating diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as an accelerated filer and is incorporated in the Netherlands. As of November 6, 2025, there were 62,291,663 ordinary shares outstanding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $3.7 million | $2.3 million | $10.5 million | $21.9 million |
| Net Loss | $(80.5) million | $(44.4) million | $(161.9) million | $(166.3) million |
| Loss Per Share (Basic/Diluted) | $(1.38) | $(0.91) | $(2.90) | $(3.42) |
| Cash and Cash Equivalents | $597.1 million | $158.9 million | $597.1 million | $251.6 million |
| Total Current Assets | $716.2 million | $390.3 million | $716.2 million | $390.3 million |
| Total Liabilities | $659.6 million | $563.3 million | $659.6 million | $563.3 million |
| Shareholders' Equity | $228.7 million | $(6.8) million | $228.7 million | $(6.8) million |
Debt and Liquidity: The company holds $50.0 million in long-term debt under a facility with Hercules Capital, Inc. A significant liability of $465.5 million is recorded for a royalty financing agreement. Liquidity was significantly bolstered by a follow-on public offering in September 2025, raising net proceeds of $323.7 million.
Material Changes vs. Prior Period
- Revenue Decline (9M): Total revenues decreased by $11.4 million year-over-year for the nine-month period, primarily due to the cessation of contract manufacturing revenues ($6.1 million in 2024 vs. $0 in 2025) and a drop in collaboration revenues ($10.6 million in 2024 vs. $0.1 million in 2025) following the divestiture of commercial manufacturing activities (Lexington Transaction) in July 2024.
- Net Loss Improvement (9M): Despite lower revenues, the net loss for the nine months ended September 30, 2025, decreased by $4.4 million compared to the prior year. This was driven by a $25.4 million foreign currency gain and a $6.0 million one-time gain from the sale of critical reagents, partially offset by increased R&D expenses related to the AMT-130 program.
- Equity Position: Shareholders' equity turned positive ($228.7 million) from a deficit ($6.8 million) at the end of 2024, largely due to the September 2025 equity offering and the release of valuation allowances related to tax benefits.
- Operating Expenses: R&D expenses increased by $3.8 million in Q3 2025 compared to Q3 2024, driven by $7.3 million in additional costs for the Huntington's disease program (AMT-130) to support BLA preparation.
Guidance, Outlook, and Risks
- AMT-130 (Huntington's Disease): The company announced positive topline data in September 2025 showing statistically significant slowing of disease progression. However, following a pre-BLA meeting with the FDA in October 2025, management believes the FDA no longer agrees that Phase I/II data compared to an external control is adequate for a BLA submission. Consequently, the timing of the BLA submission is now unclear.
- AMT-162 (ALS): Enrollment in the Phase I/II trial was voluntarily paused in September 2025 following a dose-limiting toxicity and a serious adverse event in one patient.
- Capital Resources: Management believes existing cash and investment securities ($694.2 million as of Sept 30, 2025) are sufficient to fund operations into 2029. The company has access to an additional $100 million in debt financing contingent on AMT-130 BLA approval prior to June 2027.
- Regulatory Risks: Significant uncertainty exists regarding the regulatory pathway for AMT-130. The company faces risks related to the acceptance of external control data, potential requirements for additional studies, and the impact of FDA staffing or policy changes.
- Subsequent Event: Following the November 3, 2025 announcement regarding FDA feedback, the company's share price dropped, reducing the fair value of the liability related to pre-funded warrants by $12.7 million. This gain will be recognized in Q4 2025.
Investor Verification Checklist
- BLA Pathway for AMT-130: Verify the final FDA meeting minutes and the specific requirements for additional data or trials needed to support a Biologics License Application.
- AMT-162 Safety Review: Monitor the outcome of the safety review for the paused ALS trial and the decision on whether to resume enrollment.
- Cash Burn Rate: Assess the sustainability of the current cash runway given the potential need for additional funding if the AMT-130 timeline extends beyond 2027.
- Royalty Financing Liability: Review the effective interest rate assumptions and projected cash flows for the $465.5 million royalty financing liability.
- Pre-Funded Warrants: Confirm the final fair value adjustment of the pre-funded warrant liability in the Q4 2025 filing based on year-end share prices.